Peter Nygren

Clinical characteristics and treatment outcome in p16 negative anal cancer

Burgos, Catherine; Radu, Calin; Heyman, Sofia; Cavalli-Björkman, Nina et al.

Part of Acta Oncologica, p. 633-640, 2025

DOI for Clinical characteristics and treatment outcome in p16 negative anal cancer
Download full text (pdf) of Clinical characteristics and treatment outcome in p16 negative anal cancer

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

Tabernero, Josep; Yoshino, Takayuki; Stintzing, Sebastian; de Gramont, Aimery et al.

Part of Cancer Research Communications, p. 28-37, 2024

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Lindskog, Magnus et al.

Part of BMC Pharmacology & Toxicology, 2024

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Dijkstra, E. A.; Zwart, W. H.; Nilsson, P. J.; Putter, H. et al.

Part of ESMO Open, 2023

DOI for The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Jarvius, Malin et al.

Part of BMC Cancer, 2023

Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Cashin, Peter; Söderström, Maria; Blom, Kristin; Artursson, Sara et al.

Part of British Journal of Surgery, p. 1080-1083, 2023

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Andersson, Claes; Ye, Jiawei; Blom, Kristin; Fryknäs, Mårten et al.

Part of Anti-Cancer Drugs, p. 92-102, 2023

Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats

Dahlgren, David; Rosenqvist, Evelina; Hellström, Per M.; Nygren, Peter et al.

Part of Basic & Clinical Pharmacology & Toxicology, p. 536-546, 2022

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Nyberg, Frida; Blom, Kristin; Selvin, Tove; Rudfeldt, Jakob et al.

Part of Scientific Reports, 2022

Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Bjersand, Kathrine; Blom, Kristin; Sundström Poromaa, Inger; Stålberg, Karin et al.

Part of International Journal of Oncology, 2022

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells

Karlsson, Henning; Fryknäs, Mårten; Senkowski, Wojciech; Larsson, Rolf et al.

Part of Oncology Letters, 2022

Fördelaktigt med genetisk analys före behandling med 5-fluorouracil: Utvärdering tyder på mindre biverkningar och kostnadsbesparing för sjukvården: [New recommendation on pharmacogenetic screening prior to 5-fluorouracil based cancer treatment - Swedish experience indicates less adverse effects and healthcare cost savings]

Schultz, Alice; Kohnke, Hugo; Wadelius, Mia; Nygren, Peter

Part of Läkartidningen, 2021

Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial

Demmelmaier, Ingrid; Brooke, Hannah L.; Henriksson, Anna; Mazzoni, Anne-Sophie et al.

Part of Scandinavian Journal of Medicine and Science in Sports, p. 1144-1159, 2021

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Part of Scientific Reports, 2021

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy

Rendo, Verónica; Stoimenov, Ivaylo; Mateus, André; Sjöberg, Elin et al.

Part of Nature Communications, 2020

Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial

Hauffman, Anna; Alfonsson, Sven; Bill-Axelson, Anna; Bergkvist, Leif et al.

Part of Psycho-Oncology, p. 2012-2018, 2020

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020

Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.

Forslund, Marina; Ottenblad, Anna; Ginman, Claes; Johansson, Silvia et al.

Part of Supportive Care in Cancer, p. 3331-3342, 2020

Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection

Månsson, Christopher; Nilsson, Anders; Nygren, Peter; Karlson, Britt-Marie

Part of Anticancer Research, p. 2771-2775, 2020

DOI for Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection

Experiences of a nutrition intervention: A qualitative study within a randomised controlled trial in men undergoing radiotherapy for prostate cancer

Forslund, Marina; Nygren, Peter; Ottenblad, Anna; Johansson, Birgitta

Part of Nutrition & Dietetics, p. 223-230, 2020

DOI for Experiences of a nutrition intervention: A qualitative study within a randomised controlled trial in men undergoing radiotherapy for prostate cancer

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Mody, Kabir; Mansfield, Aaron S.; Vemireddy, Lalitha; Nygren, Peter et al.

Part of Investigational new drugs, p. 684-692, 2019

DOI for A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer

Månsson, Christopher; Brahmstaedt, Richard; Nygren, Peter; Nilsson, Anders et al.

Part of Anticancer Research, p. 2509-2512, 2019

DOI for Percutaneous Irreversible Electroporation as First Line Treatment of Locally Advanced Pancreatic Cancer

Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer

Glimelius, Bengt; Nygren, Peter

Part of Acta Oncologica, p. 395-397, 2019

DOI for Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius, Bengt; Melin, Beatrice; Enblad, Gunilla; Alafuzoff, Irina et al.

Part of Acta Oncologica, p. 187-194, 2018

Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors

Daskalakis, Kosmas; Norlén, Olov; Karakatsanis, Andreas; Hellman, Per et al.

Part of Endocrine-Related Cancer, p. 471-480, 2018

DOI for Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors

Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Daskalakis, Kosmas; Norlén, Olov; Karakatsanis, Andreas; Hellman, Per et al.

Part of Neuroendocrinology, p. 189-189, 2018

DOI for Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.

Eriksson, Anna; Chantzi, Efthymia; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Leukemia Research, p. 41-46, 2017

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity

Karlsson, Henning; Fryknäs, Mårten; Strese, Sara; Gullbo, Joachim et al.

Part of Oncotarget, p. 30217-30234, 2017

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Kashif, Muhammad; Andersson, Claes; Mansoori, Sharmineh; Larsson, Rolf et al.

Part of Oncotarget, p. 103952-103967, 2017

Prognostic factors in patients with loco-regionally advanced gastric cancer

Hultman, Bo; Gunnarsson, Ulf; Nygren, Peter; Sundbom, Magnus et al.

Part of World Journal of Surgical Oncology, 2017

The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE

Hauffman, Anna; Alfonsson, Sven; Mattson, Susanne; Forslund, Marina et al.

Part of Cancer Nursing, 2017

Targeting tumor cells based on Phosphodiesterase 3A expression

Nazir, Madiha; Senkowski, Wojciech; Nyberg, Frida; Blom, Kristin et al.

Part of Experimental Cell Research, p. 308-315, 2017

DOI for Targeting tumor cells based on Phosphodiesterase 3A expression

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017

DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Blom, Kristin; Nygren, Peter; Larsson, Rolf; Andersson, Claes R.

Part of SLAS TECHNOLOGY, p. 306-314, 2017

DOI for Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer

Padhan, Narendra; Nordling, Torbjorn E. M.; Sundström, Magnus; Åkerud, Peter et al.

Part of BMC Cancer, 2016

Preclinical activity of melflufen (J1) in ovarian cancer

Carlier, Charlotte; Strese, Sara; Viktorsson, Kristina; Velander, Ebba et al.

Part of Oncotarget, p. 59322-59335, 2016

DOI for Preclinical activity of melflufen (J1) in ovarian cancer

Iron chelators target both proliferating and quiescent cancer cells

Fryknäs, Mårten; Zhang, Xiaonan; Bremberg, Ulf; Senkowski, Wojciech et al.

Part of Scientific Reports, 2016

Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids

Senkowski, Wojciech; Jarvius, Malin; Rubin, Jenny; Lengqvist, Johan et al.

Part of CELL CHEMICAL BIOLOGY, p. 1428-1438, 2016

DOI for Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids

Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy

Månsson, Christopher; Brahmstaedt, Richard; Nilsson, Anders; Nygren, Peter et al.

Part of European Journal of Surgical Oncology, p. 1401-1406, 2016

DOI for Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy

Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials

Godskesen, Tove; Kihlbom, Ulrik; Nordin, Karin; Silen, Marit et al.

Part of European Journal of Cancer Care, p. 516-523, 2016

DOI for Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials

Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

Stefansson, Måns; Nygren, Peter

Part of Acta Oncologica, p. 1227-1235, 2016

DOI for Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects

Eriksson, Anna; Gustafsson, Mats; Fryknäs, Mårten; Gullbo, Joachim et al.

Part of Haematologica, p. 367-368, 2016

Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells

Fakhoury, Isabelle; Saad, Walid; Bouhadir, Kamal; Nygren, Peter et al.

Part of Journal of nanoparticle research, 2016

DOI for Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Blom, Kristin; Nygren, Peter; Alvarsson, Jonathan; Larsson, Rolf et al.

Part of JALA, p. 178-187, 2016

DOI for Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs

Aftab, Obaid; Fryknäs, Mårten; Hassan, Saadia; Nygren, Peter et al.

Part of Chemometrics and Intelligent Laboratory Systems, p. 24-32, 2015

DOI for Label free quantification of time evolving morphologies using time-lapse video microscopy enables identity control of cell lines and discovery of chemically induced differential activity in iso-genic cell line pairs

Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

Senkowski, Wojciech; Zhang, Xiaonan; Olofsson, Maria Hagg; Isacson, Ruben et al.

Part of Molecular Cancer Therapeutics, p. 1504-1516, 2015

DOI for Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics

Senkowski, Wojciech; Zhang, Xiaonan; Nygren, Peter; Olofsson, Maria Hagg et al.

Part of Cancer Research, 2015

DOI for Spheroid-based high throughput screening for identification of molecules targeting different tumor microenvironment characteristics

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Eriksson, Anna; Österroos, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood Cancer Journal, 2015

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Kashif, Muhammad; Andersson, Claes; Hassan, Sadia; Karlsson, Henning et al.

Part of Scientific Reports, 2015

Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials

Godskesen, Tove; Hansson, Mats G.; Nygren, Peter; Nordin, Karin et al.

Part of European Journal of Cancer Care, p. 133-141, 2015

DOI for Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials

Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

Bjersand, Kathrine; Mahteme, Haile; Sundström Poromaa, Inger; Andreasson, Håkan et al.

Part of Annals of Surgical Oncology, 2015

DOI for Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Considerations on the Selection Process for Cytoreductive Surgery and Hyperthermic IntraPeritoneal Chemotherapy for Colorectal Carcinomatosis Reply

Cashin, Peter; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgery, 2015

Always look at the bright side of drugs?

Nygren, Peter

Part of Acta Oncologica, p. 145-147, 2015

DOI for Always look at the bright side of drugs?

O-15-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases

Lubberink, Mark; Golla, Sanjeep S. V.; Jonasson, My; Rubin, Kristofer et al.

Part of Journal of Nuclear Medicine, p. 1144-1149, 2015

DOI for O-15-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Hultman, Bo; Mahteme, Haile; Sundbom, Magnus; Ljungman, Martin et al.

Part of Journal of Experimental & Clinical Cancer Research, 2014

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Zhang, Xiaonan; Fryknäs, Mårten; Hernlund, Emma; Fayad, Walid et al.

Part of Nature Communications, p. 3295, 2014

Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: Long-term results from a randomized controlled trial

Pettersson, Anna; Nygren, Peter; Persson, Christina; Berglund, Anders et al.

Part of Radiotherapy and Oncology, p. 240-247, 2014

DOI for Effects of a dietary intervention on gastrointestinal symptoms after prostate cancer radiotherapy: Long-term results from a randomized controlled trial

Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome

von Heideman, Anne; Tholander, Bengt; Grundmark, Birgitta; Cajander, Stefan et al.

Part of Acta Oncologica, p. 242-250, 2014

DOI for Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome

Safety and Preliminary Efficacy of Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Localized Pancreatic Cancer

Månsson, Christopher; Bergenfeldt, Magnus; Brahmstaedt, Richard; Karlson, Britt-Marie et al.

Part of Anticancer Research, p. 289-293, 2014

A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Kashif, Muhammad; Andersson, Claes; Åberg, Magnus; Nygren, Peter et al.

Part of Molecular Cancer Therapeutics, p. 1964-1976, 2014

DOI for A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia

Eriksson, Anna; Osterros, Albin; Hassan, Sadia Bashir; Gullbo, Joachim et al.

Part of Blood, 2014

Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol

Mattsson, Susanne; Alfonsson, Sven; Carlsson, Maria; Nygren, Peter et al.

Part of BMC Cancer, p. 414, 2013

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Part of BMC Cancer, p. 374, 2013

Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Cashin, Peter H; Mahteme, Haile; Graf, Wilhelm; Karlsson, Henning et al.

Part of BMC Cancer, p. 435, 2013

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Godskesen, Tove; Nygren, Peter; Nordin, Karin; Hansson, Mats et al.

Part of Supportive Care in Cancer, p. 3137-3142, 2013

DOI for Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

Hultman, Bo; Lind, Pehr; Glimelius, Bengt; Sundbom, Magnus et al.

Part of Acta Oncologica, p. 824-830, 2013

DOI for Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Cashin, Peter H.; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgical Oncology, p. 4183-4189, 2013

DOI for Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Jarvius, Malin; Fryknäs, Mårten; D'Arcy, Padraig; Sun, Chao et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 117-123, 2013

DOI for Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells

Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

Cashin, Peter H; Ehrsson, H; Wallin, I; Nygren, Peter et al.

Part of European Journal of Clinical Pharmacology, p. 533-540, 2013

DOI for Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis

The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma

Hassan, Saadia Bashir; Gullbo, Joachim; Hu, Kefei; Berenjian, Saideh et al.

Part of Anticancer Research, p. 143-151, 2013

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

Nygren, Peter; Fryknäs, Mårten; Anagel, Bengt; Larsson, Rolf

Part of Journal of Cancer Research and Clinical Oncology, p. 2133-2140, 2013

Quality of life in peritoneal carcinomatosis after cytoreductive surgery and intraperitoneal chemotherapy

Hansson, Johan; Graf, Wilhelm; Nygren, Peter; Ring, Lena et al.

2012

Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system

Karlsson, Henning; Fryknäs, Mårten; Larsson, Rolf; Nygren, Peter

Part of Experimental Cell Research, p. 1577-1585, 2012

DOI for Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system

The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines

Häggblad Sahlberg, Sara; Spiegelberg, Diana; Lennartsson, Johan; Nygren, Peter et al.

Part of International Journal of Oncology, p. 176-184, 2012

Histopathological Classification of Pseudomyxoma Peritonei and the Prognostic Importance of PINCH Protein

Andreasson, Håkan; Wanders, Alkwin; Sun, Xiao-Feng; Willén, Roger et al.

Part of Anticancer Research, p. 1443-1448, 2012

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Haglund, Caroline; Åleskog, Anna; Nygren, Peter; Gullbo, Joachim et al.

Part of Cancer Chemotherapy and Pharmacology, p. 697-707, 2012

DOI for In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer

Hultman, Bo; Lundkvist, Jonas; Glimelius, Bengt; Nygren, Peter et al.

Part of Acta Oncologica, p. 112-121, 2012

DOI for Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer

Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Oncology, p. 647-652, 2012

Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of European Journal of Surgical Oncology, p. 509-515, 2012

The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Suzuki, C; Blomqvist, L; Sundin, Anders; Jacobsson, H et al.

Part of Annals of Oncology, p. 948-954, 2012

DOI for The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis using Serum Tumour Markers – an Observational Cohort Study

Cashin, Peter H; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of Annals of Surgery, p. 1078-1083, 2012

DOI for Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis using Serum Tumour Markers – an Observational Cohort Study

Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei

Andréasson, Håkan; Graf, Wilhelm; Nygren, Peter; Glimelius, Bengt et al.

Part of European Journal of Surgical Oncology, p. 962-968, 2012

DOI for Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei

Response to comments on 'Cytoreductive surgery and intraperitoneal chemotherapy'

Cashin, Peter H.; Graf, Wilhelm; Nygren, Peter; Mahteme, Haile

Part of European Journal of Surgical Oncology, p. 1012-1012, 2012

DOI for Response to comments on 'Cytoreductive surgery and intraperitoneal chemotherapy'

Quantitative accuracy of parametric myocardial and tumour blood flow images based on HYPR-LR-filtered dynamic [O-15]water PET

Golla, Sandeep; Sörensen, Jens; Kero, Tanja; Harms, H. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2012

Evaluation of predictive markers for patients with advanced colorectal cancer

Byström, Per; Berglund, Åke; Nygren, Peter; Wernroth, Lisa et al.

Part of Acta Oncologica, p. 849-859, 2012

DOI for Evaluation of predictive markers for patients with advanced colorectal cancer

Pseudomyxoma Peritone: symptoms, treatment, prognosis and sensitivity to cytostatic drugs in vitro

Bjersand, Kathrine; Poromaa, Inger Sundström; Nygren, Peter; Mahteme, Haile

Part of Acta Obstetricia et Gynecologica Scandinavica, p. 71-71, 2012

DOI for Pseudomyxoma Peritone: symptoms, treatment, prognosis and sensitivity to cytostatic drugs in vitro

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Gullbo, Joachim; Fryknäs, Mårten; Rickardson, Linda; Darcy, Padraig et al.

Part of Biochemical Pharmacology, p. 139-147, 2011

DOI for Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Wei, Q.; Shui, Y.; Zheng, S.; Wester, Kenneth et al.

Part of Oncology Reports, p. 3-11, 2011

DOI for EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Novel activity of acriflavine against colorectal cancer tumor cells

Hassan, Saadia; Laryea, Daniel; Mahteme, Haile; Felth, Jenny et al.

Part of Cancer Science, p. 2206-2213, 2011

DOI for Novel activity of acriflavine against colorectal cancer tumor cells

Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: a retrospective study of in vitro drug sensitivity and survival

Cashin, Peter; Nygren, Peter; Hellman, Per; Granberg, Dan et al.

Part of Clinical Colorectal Cancer, p. 108-112, 2011

DOI for Appendiceal Adenocarcinoids with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery and Intraperitoneal Chemotherapy: a retrospective study of in vitro drug sensitivity and survival

An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Byström, P.; Berglund, Åke; Nygren, Peter; Wernroth, Mona-Lisa et al.

Part of Oncology Reports, p. 1645-1652, 2010

DOI for An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Hu, Kefei; Berenjian, Saideh; Larsson, Rolf; Gullbo, Joachim et al.

Part of International Journal of Nanomedicine, p. 51-62, 2010

Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Laryea, Daniel; Gullbo, Joachim; Isaksson, Anders; Larsson, Rolf et al.

Part of Anti-Cancer Drugs, p. 33-42, 2010

DOI for Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Berglund, Åke; Byström, Per; Johansson, Birgitta; Nygren, Peter et al.

Part of Medical Oncology, p. 65-72, 2010

DOI for An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

von Heideman, Anne; Berglund, Åke; Larsson, Rolf; Nygren, Peter

Part of Cancer Chemotherapy and Pharmacology, p. 1165-1172, 2010

DOI for Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer

Byström, Per; Berglund, A.; Garske, Ulrike Garske; Jacobsson, H. et al.

Part of Annals of Oncology, p. 1057-1061, 2009

DOI for Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer

In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies

Wiberg, Kristina; Carlson, Kristina; Åleskog, Anna; Larsson, Rolf et al.

Part of Medical Oncology, p. 193-201, 2009

DOI for In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies

Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients

Laryea, Daniel; Isaksson, Anders; Wright, Colin; Larsson, Rolf et al.

Part of Investigational new drugs, p. 402-411, 2009

DOI for Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients

Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy

Hansson, Johan; Graf, Wilhelm; Påhlman, Lars; Nygren, Peter et al.

Part of European Journal of Surgical Oncology, p. 202-208, 2009

DOI for Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy

Är du ung så ska du få, men är du gammal så får du gå. Om ålderns betydelse för terapival och prioriteringar vid cancer

Nygren, Peter; Sandman, Lars

Part of Läkartidningen, p. 3417-9, 2008

Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia

Lindhagen, Elin; Eriksson, Anna; Wickström, Malin; Danielsson, Katarina et al.

Part of European Journal of Haematology, p. 344-353, 2008

DOI for Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia

Radiological assessment of tumour response to anti-cancer drugs: time to reappraise

Nygren, Peter; Blomqvist, Lennart; Bergh, Jonas; Åström, Gunnar

Part of Acta Oncologica, p. 316-8, 2008

DOI for Radiological assessment of tumour response to anti-cancer drugs: time to reappraise

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

Åleskog, Anna; Norberg, Maria; Nygren, Peter; Rickardson, Linda et al.

Part of Leukemia and Lymphoma, p. 2333-2343, 2008

DOI for Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

The fluorometric microculture cytotoxicity assay

Lindhagen, Elin; Nygren, Peter; Larsson, Rolf

Part of Nature Protocols, p. 1364-1369, 2008

DOI for The fluorometric microculture cytotoxicity assay

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Wickström, Malin; Haglund, Caroline; Lindman, Henrik; Nygren, Peter et al.

Part of Investigational new drugs, p. 195-204, 2008

DOI for The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro

Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

Mahteme, Haile; von Heideman, Anne; Grundmark, Birgitta; Tholander, B. et al.

Part of European Journal of Surgical Oncology, p. 547-552, 2008

DOI for Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines

Fryknäs, Mårten; Dhar, Sumeer; Öberg, Fredrik; Rickardson, Linda et al.

Part of International Journal of Cancer, p. 189-195, 2007

DOI for STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines

Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Quartino, Angelica; Karlsson, Mats O.; Freijs, Agneta; Jonsson, Niclas et al.

Part of Journal of clinical pharmacology, p. 1014-1021, 2007

DOI for Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

Lindman, Henrik; Åström, Gunnar; Ahlgren, Johan; Villman, Kenneth et al.

Part of Acta Oncologica, p. 165-171, 2007

DOI for Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

The pharmacist and quality of cancer chemotherapy.

Nygren, Peter

Part of Acta Oncologica, p. 715-716, 2007

DOI for The pharmacist and quality of cancer chemotherapy.

Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro

Lindhagen, Elin; Rickardson, Linda; Elliott, Gary; Leoni, Lorenzo et al.

Part of Investigational new drugs, p. 297-303, 2007

DOI for Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Wickström, Malin; Danielsson, Katarina; Rickardson, Linda; Gullbo, Joachim et al.

Part of Biochemical Pharmacology, p. 25-33, 2007

DOI for Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients

Screening of an annotated compound library for drug activity in a resistant myeloma cell line

Rickardson, Linda; Fryknäs, Mårten; Haglund, Caroline; Lövborg, Henrik et al.

Part of Cancer Chemotherapy and Pharmacology, p. 749-758, 2006

DOI for Screening of an annotated compound library for drug activity in a resistant myeloma cell line

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Fryknäs, Mårten; Rickardson, Linda; Wickström, Malin; Dhar, Sumeer et al.

Part of Journal of Biomolecular Screening, p. 457-468, 2006

DOI for Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model

Accuracy of assessment of distress, anxiety, and depression by physicians and nurses in adolescents recently diagnosed with cancer

Hedström, Mariann; Kreuger, Anders; Ljungman, Gustaf; Nygren, Peter et al.

Part of Pediatric Blood & Cancer, p. 773-9, 2006

DOI for Accuracy of assessment of distress, anxiety, and depression by physicians and nurses in adolescents recently diagnosed with cancer

Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Lövborg, Henrik; Öberg, Fredrik; Rickardson, Linda; Gullbo, Joachim et al.

Part of Int J Cancer, p. 1577-1580, 2006

DOI for Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram

Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study.

Persson, Christina; Glimelius, Bengt; Rönnelid, Johan; Nygren, Peter

Part of Nutrition, p. 170-8, 2005

Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia

Frost, B M; Forestier, E; Gustafsson, G; Nygren, Peter et al.

Part of Leukemia, p. 165-169, 2005

DOI for Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

Sandström, M; Lindman, Henrik; Nygren, Peter; Lidbrink, E et al.

Part of J Clin Oncol, p. 413-21, 2005

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles

Rickardson, Linda; Fryknäs, Mårten; Dhar, Sumeer; Lövborg, Henrik et al.

Part of British Journal of Cancer, p. 483-492, 2005

Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage.

Palle, J; Frost, B M; Forestier, E; Gustafsson, G et al.

Part of Br J Haematol, p. 189-98, 2005

[Limit investigation in cancer of unknown primary site]

Berglund, Ake; Nygren, Peter; Hagberg, Hans; Pahlman, Lars et al.

Part of Lakartidningen, p. 2946-8, 2950, 2005

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.

Nygren, Peter; Hande, Kenneth; Petty, Kevin J; Fedgchin, Margaret et al.

Part of Cancer Chemother Pharmacol, p. 609-16, 2005

Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.

Villman, Kenneth; Blomqvist, Carl; Larsson, Rolf; Nygren, Peter

Part of Anticancer Drugs, p. 609-15, 2005

In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.

Åleskog, Anna; Larsson, Rolf; Höglund, Martin; Kristensen, Jörgen et al.

Part of Anticancer Drugs, p. 277-83, 2005

Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828

Lövborg, Henrik; Nygren, Peter; Larsson, Rolf

Part of Molecular Cancer Therapeutics, p. 521-526, 2004

Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia.

Frost, Britt-Marie; Forestier, Erik; Gustafsson, Göran; Nygren, Peter et al.

Part of Blood, p. 2452-7, 2004

DOI for Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia.

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.

Mahteme, H; Hansson, J; Berglund, Åke; Påhlman, Lars et al.

Part of Br J Cancer, p. 403-7, 2004

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguadine CHS 828

Gullbo, Joachim; Lövborg, Henrik; Dhar, Sumeer; Lukinius, Agneta et al.

Part of Anti-Cancer Drugs, p. 45-54, 2004

VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia

Åleskog, Anna; Tobin, Gerard; Laurell, Anna; Thunberg, Ulf et al.

Part of Eur J Haematol, p. 407-411, 2004

Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.

Hovstadius, Peter; Lindhagen, Elin; Hassan, Sadia; Nilsson, Kenneth et al.

Part of Anticancer Drugs, p. 63-70, 2004

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Gullbo, Joachim; Lindhagen, Elin; Bashir-Hassan, Saadia; Tullberg, Marcus et al.

Part of Invest New Drugs, p. 411-20, 2004

Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia

Frost, Britt-Marie; Nygren, Peter; Gustafsson, G; Forestier, E et al.

Part of British Journal of Haematology, p. 376-385, 2003

DOI for Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia

Structure activity relationship for alkylating dipeptide nitrogen mustard derivatives

Gullbo, Joachim; Tullberg, Marcus; Våbeno, Jon; Ehrsson, Hans et al.

Part of Oncology Research, p. 113-132, 2003

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-melphalanyl-p-L-fluorophenylalanine ethyl ester): Comparison with its m-L-sarcolysin analogue P2

Gullbo, Joachim; Wallinder, Charlotta; Tullberg, Marcus; Lövborg, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1331-1339, 2003

Antitumor activity of the alkylating oligopeptides J1(L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2(L-prolyl-m-L-fluorophenylalanine ethyl ester):comparison with melphalan.

Gullbo, Joachim; Dhar, Sumeer; Luthman, K; Ehrsson, H et al.

Part of Anticancer Drugs., p. 617, 2003

Increased in vitro cellular drug resistance is related to poor outcome inhigh-risk childhood acute lymphoblastic leukaemia.

Frost, BM; Nygren, Peter; Gustafsson, G; Forestier, E et al.

Part of Br J Haematol, p. 376, 2003

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

Gullbo, Joachim; Wickström, Malin; Tullberg, M; Ehrsson, H et al.

Part of J Drug Target., p. 355, 2003

Overview of the clinical efficacy of investigational anticancer drugs.

Nygren, Peter; Larsson, Rolf

Part of J Intern Med., p. 46, 2003

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.

Henningsson, A; Sparreboom, A; Sandström, M; Freijs, A et al.

Part of Eur J Cancer., p. 1105, 2003

In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia

Frost, Britt-Marie; Lönnerholm, Gudmar; Nygren, Peter; Larsson, Rolf et al.

Part of Anti-Cancer Drugs, p. 735-742, 2002

Selection of chemotherapy by ex vivo assessment of tumor sensitivity tocytotoxic drugs: results of a clinical trial.

Berglund, A; Glimelius, B; Bergh, J; Brodin, O et al.

Part of Med Oncol, p. 151, 2002

Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.

Ekelund, Sara; Persson, I; Larsson, Rolf; Nygren, Peter

Part of Chemotherapy, p. 196, 2002

Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells.

Ekelund, Sara; Larsson, Rolf; Nygren, Peter

Part of Anticancer Res, p. 2269, 2002

The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro from cytotoxic synergy to complete inhibition of apoptosis.

Martinsson, Petra; Ekelund, Sara; Nygren, Peter; Larsson, Rolf

Part of Br J Pharmacol, p. 568, 2002

In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin´s lymphoma.

Åleskog, Anna; Jonsson, Elin; Larsson, Rolf; Nygren, Peter et al.

Part of Br J Haematol, p. 563, 2002

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.

Lövborg, Henrik; Martinsson, Petra; Gullbo, Joachim; Ekelund, Sara et al.

Part of Biochem Pharmacol, p. 1491, 2002

Assessment of drug activity and proliferation ex vivo for prediction ofoutcome in aggressive non-Hodgkin's lymphomas.

Ericsson, SM; Larsson, Rolf; Nygren, Peter; Sundstrom, C et al.

Part of Acta Oncol, p. 36, 2002

A hollow fiber model for in vitro studies of cytotoxic compounds: activityof the cyanoguanidine CHS 828.

Hassan, Saadia B; de la Torre, M; Nygren, Peter; Karlsson, MO et al.

Part of Anti-Cancer Drugs, p. 33, 2001

Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells.

Martinsson, Petra; de la Torre, M; Binderup, L; Nygren, Peter et al.

Part of Eur J Pharmacol, p. 181, 2001

Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.

Ekelund, Sara; Nygren, Peter; Larsson, Rolf

Part of Biochem Pharmacol, p. 1183, 2001

Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis (guanylhydrazone).

Ekelund, Sara; Sjoholm, Å; Nygren, Peter; Binderup, L et al.

Part of Eur J Pharmacol, p. 39, 2001

In vivo activity of CHS 828 on hollow-fibre cultures of primary humantumour cells from patients.

Jonsson, Elin; Friberg, LE; Karlsson, MO; Hassan, Saadia B et al.

Part of Cancer Lett, p. 193, 2001

Characteristics of etoposide induced apoptopic cell death in the U-937 human lymphoma cell line.

Martinsson, Petra; Liminga, Gunnar; Nygren, Peter; Larsson, Rolf

Part of Anti-Cancer Drugs, p. 699, 2001

Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB.

Liminga, Gunnar; Martinsson, Petra; Jonsson, B; Nygren, Peter et al.

Part of Biochem Pharmacol, p. 1751, 2000

Antitumor effect of suramin analogues in human tumour cell lines and primary cultures of tumour cells

Dhar, Sumeer; Gullbo, Joachim; Csoka, Katalin; Eriksson, E et al.

Part of Eur J Cancer, p. 803, 2000

Differential activity of topotecan, irinotecan and SN-38 in primary cultures of human tumor cells but not in cell lines.

Jonsson, Elin; Dhar, Sumeer; Jonsson, B; Nygren, Peter et al.

Part of Eur J Cancer, p. 2120, 2000

Cellular cytotoxic drug sensitivity in children with leukemia and Down´s syndrome: an explanation differences in clinical outcome?

Frost, BM; Gustafsson, G; Nygren, Peter; Larsson, Rolf et al.

Part of Leukemia, 2000

Publications

Recent publications

All publications

Articles in journal

Articles, review/survey

Manuscripts (preprints)